FDA Approved: ERBITUX — Supplemental Application (ImClone LLC)

View source ↗

Summary

The FDA approves a supplemental application for Erbitux (cetuximab) filed by ImClone LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

SUPPL AP for ERBITUX (CETUXIMAB)